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Abstract
Background: Extravasation of circulating cancer cells is a key event of metastatic dissemination that is initiated by
the adhesion of cancer cells to endothelial cells. It requires interactions between adhesion receptors on endothelial
cells and their counter-receptors on cancer cells. Notably, E-selectin, a major endothelial adhesion receptor,
interacts with Death receptor-3 present on metastatic colon carcinoma cells. This interaction confers metastatic
properties to colon cancer cells by promoting the adhesion of cancer cells to endothelial cells and triggering the
activation of the pro-migratory p38 and pro-survival ERK pathways in the cancer cells. In the present study, we
investigated further the mechanisms by which the E-selectin-activated pathways downstream of DR3 confer a
survival advantage to colon cancer cells.
Methods: Cell survival has been ascertained by using the WST-1 assay and by evaluating the activation of the PI3
kinase/NFB survival axis. Apoptosis has been assayed by determining DNA fragmentation by Hoechst staining and
by measuring cleavage of caspases-8 and -3. DR3 isoforms have been identified by PCR. For more precise
quantification, targeted PCR reactions were carried out, and the amplified products were analyzed by automated
chip-based microcapillary electrophoresis on an Agilent 2100 Bioanalyzer instrument.
Results: Interaction between DR3-expressing HT29 colon carcinoma cells and E-selectin induces the activation of
the PI3K/Akt pathway. Moreover, p65/RelA, the anti-apoptotic subunit of NFB, is rapidly translocated to the
nucleus in response to E-selectin. This translocation is impaired by the PI3K inhibitor LY294002. Furthermore,
inhibition of the PI3K/Akt pathway increases the cleavage of caspase 8 in colon cancer cells treated with E-selectin
and this effect is still further increased when both ERK and PI3K pathways are concomitantly inhibited. Intriguingly,
metastatic colon cancer cell lines such as HT29 and SW620 express higher levels of a splice variant of DR3 that has
no trans-membrane domain and no death domain.
Conclusion: Colon cancer cells acquire an increased capacity to survive via the activation of the PI3K/NFB
pathway following the stimulation of DR3 by E-selectin. Generation of a DR3 splice variant devoid of death domain
can further contribute to protect against apoptosis.
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The metastatic process consists of a number of sequen-
tial interrelated steps, all of which must be completed
successfully to give rise to a secondary tumor [1-3]. In
particular, the adhesion of cancer cells to endothelial
cells is a prerequisite for extravasation of circulating
cancer cells and for their metastatic dissemination. This
adhesive event requires specific interactions between
adhesion receptors present on vascular endothelial cells
and their ligands or counter-receptors on cancer cells.
E-selectin is a specific endothelial adhesion receptor that
is induced by pro-inflammatory stimuli. Its natural func-
tion is to mediate the adhesion of leukocytes to the
endothelium allowing their extravasation into inflamed
tissues [4]. Intriguingly, cancer cells hijack the inflam-
matory system and interact with E-selectin to extrava-
sate [5,6]. For example, colon carcinoma cells adhere to
and roll on both purified E-selectin and cytokine-stimu-
lated endothelial cells either in static or dynamic condi-
tions in vitro [7-9]. Moreover, several studies strongly
support the role of E-selectin-mediated adhesion of can-
cer cells to endothelial cells as an important determi-
nant of metastasis, especially of colon carcinoma cells.
In particular, the binding efficiency of clonal colon can-
cer cell lines to E-selectin is directly proportional to
their respective metastatic potential [10]. In contrast,
anti-E-selectin antibodies and antisense oligonucleotides
that inhibit E-selectin expression impair experimental
liver metastasis of murine and human tumor cells
[11,12]. Similarly inhibiting the expression of E-selectin
with cimetidine, an antagonist of histamine H2 recep-
tors, inhibits the adhesion of cancer to endothelial cells
and impairs metastatic dissemination [13].
The binding of cancer cells to E-selectin involves a
counter-receptor for E-selectin that is composed of sialyl
Lewis-a/x carbohydrate determinants that are borne by a
carrier protein or lipids on cancer cells. The binding is
Ca
2+-dependent and is mediated through the N-terminal
lectin domain of E-selectin. Sialyl Lewis-a on carrier
proteins plays a major role in E-selectin binding of can-
cer cells derived from the lower digestive organs, such
as the colon and rectum, as well as from the pancreas
and biliary tract [14]. On the other hand, sialyl Lewis-x
is the representative carbohydrate involved in the E-
selectin binding of breast, ovarian and pulmonary cancer
cells [1]. Little is known about the proteins that bear
these carbohydrates and that serve as the E-selectin
counter-receptor backbone on cancer cells. LAMP-1,
LAMP-2, CD44, CEA and podocalyxin-like proteins
were all identified as E-selectin counter-receptors on
colon cancer cells [15-19]. However, the signaling events
that stem from these receptors in the cancer cells
bound to E-selectin are still ill defined. Several studies
have shown that the adhesion of cancer cells to E-
selectin initiates a reverse signaling in the cancer cells,
which raises the possibility that this signaling modulates
the metastatic potential of cancer cells [20-22]. We pre-
viously reported that Death receptor-3 (DR3) is a func-
tional and signaling sialylated ligand that binds E-
selectin on colon cancer cells [20,23]. The subsequent
DR3 activation induced by E-selectin increases the
motile potentials of the cancer cells through activation
of the p38 MAP kinase pathway [20,23].
DR3 is a member of the second group of the TNF
receptor (TNFR) superfamily that includes TNFR1, DR4,
DR5, DR6, and Fas [17]. These receptors contain a com-
mon 70- to 80-amino acid homologous region in the
cytoplasmic tail called the death domain [24]. The sig-
naling pathways leading to cell death in response to
these receptors are similar and rely on trimerization and
oligomerization of the receptors upon ligand binding
followed by the recruitment of death domain proteins,
such as TRADD, FAD, or RIP1, and subsequently, acti-
vation of the apoptotic cascade [25]. More recently, it
was reported that CD95/Fas, a member of the TNFR
family, induces signaling to phosphatidylinositol 3-kinase
(PI3K) via phosphorylation of Tyr residues present in its
death domain [26]. Several splice isoforms of DR3 exists,
some of which such as, isoforms 1, 2, 3, 4 and 7, contain
a death domain, while others, such as the truncated DR3
isoform 12, do not [27]. Among these variants, DR3 iso-
form 2 (DR3v2) is the major and parental member of
the family and is referred to hereafter as DR3. Interest-
ingly, the splicing profile of DR3 may be altered in can-
cer. Notably, DR3b differs from DR3 by the inclusion of
a 28 amino-acid stretch in the extracellular domain.
Whereas DR3 is expressed in all cell lines and lym-
phoma samples tested, DR3b expression is restricted to
lymphoid T-cell and immature B-cell lines and to some
cases of follicular lymphoma. This suggests that several
receptor isoforms can participate in lymphoid cell
homeostasis [28]. The functions of DR3 in a physio-
pathologic context are unclear. However, its ectopic
expression in mammalian cells induces apoptosis or
activates the pro-survival transcription factor NFB,
depending on the cytoplasmic effectors engaged in the
signaling complexes downstream of the death domain
[29,30]. Intriguingly, the activation of DR3 by TL1A/
VEGI, the cognate ligand for DR3 is not followed by
apoptosis in human erythroleukemic TF-1 cells. This is
presumably because it is associated with the expression
of the apoptosis-inhibiting protein c-IAP2 [31,32]. More
recently, we found that activation of DR3 by E-selectin
increased the survival of LoVo colon cancer cells, in
part by activating the ERK pathway [23].
In this study, we further investigated the mechanisms
by which activation of DR3 by E-selectin increases the
survival of colon carcinoma cells. Our major finding is
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apoptosis in response to E-selectin in part because they
bind to DR3 to activate the PI3K/NFB survival pathway
and in part because they generate an alternative splice
variant of DR3 that lacks trans-membrane and death
domains, thus rendering it unable to induce apoptosis.
Methods
Reagents and antibodies
Recombinant human E-selectin/Fc (rhE-selectin/Fc) was
obtained from R&D Systems (Minneapolis, MN). Pheny-
lethylisothiocyanate (PEITC) and LY294002 were pur-
chased from Sigma (St Louis, MO). Calcein-AM was
obtained from Invitrogen-Molecular Probes (Burlington,
ON, Canada). Dimethylsulfoxyde was purchased from
Fisher (Montreal, QC, Canada). Protein G-sepharose was
purchased from GE Healthcare (Mississauga, ON,
Canada). PP2 and PD098059 were purchased from Calbio-
chem (Mississauga, ON, Canada). Rabbit anti-DR3 clone
H300 was obtained from Santa Cruz biotechnology,
mouse anti-DR3 extracellular domain (DR3ecd), mouse
anti-vinculin (hVIN-1), rabbit anti-active caspase 3, and
irrelevant mouse IgG1 (MOPC21) were purchased from
Sigma (St Louis, MO). Mouse anti-DR3 clone B65 was
obtained from Millipore (Nepean ON, Canada). Mouse
anti-DR3 (hDR3) was purchased from R&D Systems (Min-
neapolis, MN). Rabbit anti-phospho Akt (Ser 473), rabbit
anti-Akt, rabbit anti-NFB p65 and mouse anti-caspase 8
(1C12) were all obtained from Cell Signaling Technology,
(Beverly, MA). Mouse anti-TATA Binding Protein (TBP)
antibody was purchased from AbCam (Cambridge, MA).
Goat anti-mouse IgG (H+L) and goat anti-rabbit IgG (H
+L) conjugated with horseradish peroxidase were from
Jackson Immunoresearch (West Grove, PA).
Cells
HT29 colorectal adenocarcinoma cells were cultivated in
McCoy 5A medium supplemented with 10% foetal bovine
s e r u m( F B S )a n da n t i b i o t i cs. HT29LMM (highly meta-
static HT29 cells) and Jurkat T cells were cultivated in
RPMI medium containing 10% FBS. Caco2 colorectal ade-
nocarcinoma cells were grown in DMEM high glucose
medium supplemented with 10% FBS and Glutamax 1X.
SW480 and SW620 are colorectal adenocarcinoma cells
isolated from the primary site and lymph node secondary
site from the same patient. They were cultivated in Leibo-
vitz medium L15 containing 10% FBS. LoVo colorectal
adenocarcinoma cells grade IV were grown in Ham F12K
medium supplemented with 10% FBS. HIEC cells are nor-
mal human intestinal epithelial cells that were cultivated
in OptiMEM containing 5% FBS and 5 ng/ml EGF [33].
HEK293, HeLa, MDA MB231 and MCF7 cells were culti-
vated in DMEM containing 10% foetal calf serum. All
these cell lines were obtained from ATCC.
Human umbilical vein endothelial cells (HUVEC) were
isolated by collagenase digestion of umbilical veins from
undamaged sections of fresh cords, as described [34].
The cells used at passages ≤ 5 were grown to confluence
in gelatin-coated tissue culture flasks in medium 199
containing 20% heat-inactivated FBS, endothelial cell
growth supplement (60 μg/ml), glutamine (2 mM),
heparin (25000 IU). Human micro-capillary endothelial
cells (HMEC) were cultivated in MCDB medium con-
taining 10% FBS, 1 μg/ml hydrocortisone and 10 ng/ml
EGF. All cells lines were cultivated in the presence of
antibiotics and maintained at 37°C in a 5% CO2 humidi-
fied atmosphere.
Adhesion assays in a laminar flow chamber
HUVEC were trypsinized and grown for 24 hrs on gela-
tin-coated slides. These endothelial cells were treated
with 20 ng/ml IL-1b for 4 h to induce the expression of
E-selectin. The cultures were then placed in the laminar
flow chamber GlycoTech (Gaithersburg, MD, USA)
under a shear stress of 1 dyne/cm
2. In certain experi-
ments, anti-human DR3 monoclonal Ab clone B65 or
MOPC21 irrelevant antibody were added in the culture
medium of HT29 cells, 30 min before their injection in
the chamber. In other experiments, a knockdown of
DR3 was performed by small interfering RNA, as pre-
viously described [9,23]. Briefly, HT29 cells were trans-
fected by electroporation with human DR3 siRNA
( s i R N A ;s e n s e ,5 ’-CCGUCCAGUUGGUGGGUAA-3’,
and antisense, 5’-UUACCCACCAACUGGACGG-3’)o r
control siRNA purchased from Qiagen (Mississauga,
ON, Canada). Tumor cells in suspension (2 × 10
6 per
assay) were labeled for 30 min with Calcein AM and
washed twice with M199 medium before being added
into the flow chamber. Videos were taken directly using
a camera mounted on a TE2000 fluorescence micro-
scope at ×20 magnification (Nikon, Melville, NY, USA).
Survival assay
Twenty-four hours after being plated, HT29 cells were
left to grow for 96 hours with or without E-selectin or
with the apoptosis inducer curcumin (75 μM) [35]. At
the end of the treatments, the cell survival was evaluated
with the Quick Cell Proliferation Assay Kit from BioVi-
sion (Mountain View, CA). The test evaluates the ability
of viable cells to convert tetrazolium salt into formazan
(WST-1 assay), which can be monitored at 450 nm.
PI3 kinase and NFB activation
Cells were washed twice and incubated in serum-free
medium for 2 hours in the presence or not of the inhi-
bitors (LY294002 or PP2). Thereafter, rhE-selectin was
added for different periods of time. Cell extracts were
prepared and PI3K and NFB activation were assayed in
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Akt at Ser 473 and nuclear translocation of p65NFB,
respectively.
Extraction of nuclear proteins in denaturing conditions
The protocol was adapted from Andrews and Faller
[36]. Cells were washed 3 times in PBS and were re-sus-
pended in 1.6 ml of PBS. The cell suspension was briefly
vortexed and 100 μl of total extract were collected and
mixed in 20 μl of extraction buffer. The rest of the cell
suspension was centrifuged (16,000 × g) for 10 seconds
at 4°C, and the pellet was resuspended in 400 μlo fb u f -
fer A (10 mM HEPES-NaOH pH 7.9, 1.5 mM MgCl2,
10 mM KCl, 0.5 mM DDT, 0.2 mM PMSF). The extract
was left on ice for 10 min, vortexed for 10 seconds and
centrifuged for 10 seconds at 4°C. The supernatant was
removed and discarded, and the pellet was resuspended
in 70 μl of buffer C (20 mM HEPES-NaOH pH 7.9, 25%
glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
0.5 mM DDT, 0.2 mM PMSF). The samples were incu-
bated on ice for 20 minutes and centrifuged for 2 min
at 4°C. Extraction buffer was added in each extract
before heating. The amount of proteins was quantified
by the Lowry method.
DR3 sequencing
Total RNA was extracted from (1 × 10
6) cells using Qia-
gen RNeasy kit (Mississauga, ON, Canada). All RNA sam-
ples were stored at -80°C until assay. The mRNA was
reverse-transcribed with Qiagen Sensiscript reverse tran-
scription kit using random hexamers. Nested PCRs were
used to amplify a fragment of the tnfrsf25 gene using spe-
cific pairs of primers and the Qiagen Hotstart taq DNA
polymerase kit according to the manufacturer protocol
(PCR1-Forward primers: 5’-CGTCGGAGGGCTATG-
GAGCAGC-Reverse primers: 5’-GGCCGGCTG GTGC
TGCTACGC. PCR2-Forward primers: 5’-GAG GATC-
CATGCAGGGCGGCACTCGTAGC-Reverse primers: 5’-
ACCTCGAGTCACGGGCCGCGCTGCAG). PCR pro-
ducts were cloned in pcDNA3 (Invitrogen, Burlington
ON, Canada) vector and were sequenced by CRCHUQ/
CHUL sequencing platform (Québec Qc, Canada). The
DR3 sequences were compared with those found in the
BLAST database and analyzed with the Human Genome
Browser Gateway http://genome.ucsc.edu/cgi-bin/hgGate-
way and the AceView genes http://www.ncbi.nlm.nih.gov/
IEB/Research/Acembly/ databases.
Analysis of DR3 variants
Total RNA was extracted from (1 × 10
6) cells using Qia-
gen RNeasy kit and one μg was used for a reverse tran-
scription using Omniscript reverse transcriptase
(Qiagen). Then, the full length DR3 was amplified by
PCR using Qiagen Hotstart polymerase and the
following primers: 5’-CGTCGGAGGGCTATGGAG-
CAGC and 5’-GGCCGGCTGGTGCTGCTACGC fol-
lowing the manufacturer’s instructions. Thereafter, the
region from exon 5 to exon 7 of DR3 was amplified by
PCR, as previously described, using DR3 full length PCR
product as a template and the following primers: 5’-
CCCGCAGA GATACTGACTGTGGGAC and 5’-
GTAGCCAGGGG TCCAGCTGTTACC. The resulting
products were separated by agarose gel electrophoresis.
For more precise quantification, targeted PCR reac-
tions were carried out, and the amplified products were
analyzed by automated chip-based microcapillary elec-
trophoresis on an Agilent 2100 Bioanalyzer instrument
(Agilent Technologies, Santa Clara, CA) as previously
described [37]. Amplicon sizing and relative quantifica-
tion was performed by the manufacturer’ss o f t w a r e .T h e
primers used were Forward: 5’-TTCCCGCAGAGA TA
CTGACTG and Reverse: 5’-AGCACCTGG ACCCA
GAACA.
Western blotting
Cells lysis was done at 4°C in extraction buffer (60 mM
Tris-base, pH 6.8, 10% glycerol, and 3% sodium dodecyl
sulphate) added with 5% b-mercaptoethanol just before
use. Then, lysates were boiled, vortexed twice and cen-
trifuged at 13,000 g for 5 minutes. Proteins were sepa-
rated by SDS-PAGE and transferred to a nitrocellulose
membrane. Each antibody was used according to the
manufacturer’s protocol. Blots were then revealed with
Super signal West pico kit obtained from Pierce Bio-
technology Inc (Rockford IL). If necessary, the mem-
brane was reprobed for normalization.
Apoptosis evaluation
1) by DNA fragmentation. HT29 cells were treated with
rhE-Selectin/Fc at 10 μg/ml for 4 hours or 24 hours, or
were treated with phenethyl isothiocyanate at 50 μM for
24 hours. Cells were washed twice with PBS, fixed with
3,7% formaldehyde and stained with Hoechst for 60 min
at room temperature in the dark. The cells were exam-
ined with a Nikon Eclipse 800 equipped with a 40 ×
objective lens. 2) by caspase activation.C a s p a s e8a n d3
activities were evaluated by western blotting using anti-
caspase 8 and anti active-caspase-3 antibodies. The
assays were performed on pools of cells containing both
floating and adhering cells.
Results and Discussion
Death receptor-3 mediates the adhesion of colon cancer
cells to endothelial cells expressing E-selectin under flow
conditions
We previously reported that the adhesion of HT29
colon cancer cells to endothelial cells under static con-
ditions is mediated by the binding interaction between
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by endothelial cells [23,38]. Considering that the adhe-
sion of cancer cells to the endothelium in vivo occurs
under flow and shear stress conditions, we ascertained
the role of DR3 in mediating adhesion of colon cancer
cells to E-selectin under flow conditions using a laminar
flow chamber.
HUVEC forming a tight monolayer on gelatin-coated
glass slides were treated or not for 4 hours with IL-1b
to induce the expression of E-selectin. Then, the cul-
tures were placed in a laminar flow chamber in which
medium circulated under a flow that gave a physiologi-
cal shear stress of 1 dyne/cm
2 [9]. Live HT29 cells (2 ×
10
6 per assay) stained with Calcein AM and pre-treated
or not with anti-DR3 antibody or an siRNA that knocks
down the expression of DR3 were injected in the flow
system and video sequences were taken at 25 minute
intervals. The cells attached to the endothelium were
counted in more than 5 fields per condition. Results
showed that, after the first 25 min, no HT29 cancer cell
adhered to endothelial cells that did not express E-selec-
tin. However, they adhered in a time-dependent manner
to HUVEC expressing E-selectin and the adhesion was
blocked by treating the endothelial layer with an anti-
Eselectin antibody (data not shown and [9]). These find-
ings clearly indicated that the adhesion of HT29 cells to
endothelial cells was E-selectin-dependent. As shown in
Figure 1A-F(and additional files 1, 2, 3 and 4), the adhe-
sion was also DR3-dependent given that inhibiting DR3
with the anti-DR3 antibody or knocking down its
expression with siRNA led to a 7-fold reduction of the
adhesion of HT29 cells to HUVEC expressing E-selectin.
These results suggest that the adhesion of colon cancer
cells in blood circulation relies mainly on DR3/E-selectin
interaction. In a previous study, we described three dis-
tinct mechanisms by which circulating cancer cells inter-
act with E-selectin to initiate transendothelial migration:
formation of a mosaic between cancer cells and endothe-
lial cells, paracellular diapedesis at the junction of three
endothelial cells, and transcellular diapedesis [9]. The
results of the present study now suggest that DR3
expressed by colon cancer cells is a major partner of E-
selectin in inducing these mechanisms of diapedesis in
vivo. In particular, it is possible that DR3 binding to E-
selectin is the initial event that activates E-selectin oligo-
merization and thereby ERK-mediated disruption of the
adherent junctions and diapedesis [38]. Another possibility
is that the DR3/E-selectin binding triggers the release of
chemokines or cytokines, such as VEGF, by endothelial
cells or cancer cells, which later triggers diapedesis [39,40].
E-selectin does not induce apoptosis in HT29 cells
DR3 is a member of the TNF receptor family whose
activation is typically associated with apoptosis [24].
Along these lines, the ectopic expression of DR3 in
HEK293 or HeLa cells induced marked apoptosis [30].
Accordingly, we next investigated whether the activation
of DR3 by E-selectin triggers apoptosis. We found that
chimeric rhE-selectin/Fc taken as ligand did not induce
apoptosis in HT29 cells, even at concentrations twice as
those required to induce DR3-mediated activation of
p38 [23]. This is illustrated in Figure 2A-C which shows
that rhE-selectin/Fc at a concentration of 10 μg/ml did
not induce nuclear fragmentation even after 24 h expo-
sure. In contrast, phenylethyl isothiocyanate, a death
receptor-independent inducer of apoptosis in these cells
exerted a strong apoptotic response [41,42] (Figure 2D).
Consistent with these findings, we found that E-selectin,
in contrast to curcumin, did not reduce cell survival
even after 96 h of exposure, as determined by the
WST-1 assay (Figure 2E). In the in vivo context, these
results suggest that the DR3-mediated adhesion of colon
cancer cells to endothelial cell E-selectin may trigger
activation of survival pathways in cancer cells that
impair apoptosis.
E-selectin-induced activation of Death receptor-3 triggers
the activation of PI3K in a Src kinase-dependent manner
Inhibition of ERK is associated with a weak increase in
the activation of caspase-3 in LoVo colon cancer cells
treated by rhE-selectin/Fc [23]. This suggests that
another pathway is involved in conferring resistance to
apoptosis to colon cancer cells adhering to E-selectin.
We thus evaluated the contribution of the PI3K pathway
given that it is a major pro-survival pathway. By measur-
ing the phosphorylation of AKT at Ser473 (Figure 3A),
we found that exposure of HT29 cells to rhE-selectin/Fc
induced a time-dependent activation of PI3K which
peaked at 15 min. The activation of PI3K by E-selectin
is dependent on DR3 activation given that it was abol-
ished by two DR3 neutralizing antibodies (Figure 3B).
Interestingly, the E-selectin-induced phosphorylation of
Akt at Ser473 was sensitive to LY294002, a well-known
inhibitor of PI3K activity (Figure 3C). In line with the
findings that showed that PI3K activation was down-
stream of Src in response to different cytokines includ-
ing TNFa, we found that the phosphorylation of Akt at
Ser473 was also sensitive to Src inhibition by the pan
Src inhibitor PP2 (Figure 3D)[43,44]. Interestingly, DR3
contains an ITAM motif within its death domain that
harbors two tyrosine residues (Y376 and Y394) that
have been suggested to be phosphorylated via Src activa-
tion [45]. In light of our results, it is thus possible that
Src-dependent activation of the PI3K pathway may ori-
ginate from an Src-mediated phosphorylation of one of
these tyrosines. Hence, these findings suggest that E-
selectin-mediated activation of Src may trigger phos-
phorylation of DR3 which would converge on the
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survival [46]. Accordingly, we next investigated the sig-
naling events by which the activation of PI3K down-
stream of DR3 may mediate the survival of colon cancer
cells.
The activation of PI3K downstream of DR3 induces the
activation of NFB
Earlier findings have highlighted the point that, depend-
ing on cell types and cellular context, DR3 activation
was associated either with apoptosis following the
recruitment of the apoptotic cascade on the death
domain, or survival following activation of the pro-survi-
val factor NFB [31]. Hence, we next investigated the
status of NFB following activation of DR3 by E-selec-
tin. As shown in Figure 4, we found that E-selectin
induced a LY294002-sensitive and thereby PI3K-depen-
dent activation of NFB, as evaluated by the transloca-
tion of NFB-p65 subunit into the nucleus (Figure 4).
Previous studies have reported that NFB was activated
by DR3 and other TNFR following the activation of
NFB-inducing kinase downstream of the recruitment
of TRAF2 to the receptor death domain [47,48]. In turn,
this leads to increased survival [29,31,49]. Here our
Figure 1 DR3 mediates the adhesion of colon cancer cells to E-selectin-expressing endothelial cells in a laminar flow chamber. At oC .
HUVECs were stimulated with 20 ng/mL of IL-1b for 4 h. Live HT29 cells (2 × 10
6 per assay) stained with Calcein AM were treated with anti-DR3
blocking antibody (B65) or with a control irrelevant antibody (Ctrl: MOPC21) for 30 min prior to being introduced in the circulating medium. D
to F. The knockdown of DR3 expression in HT29 was performed by small interfering RNA (siDR3). siRNA targeting unrelated mRNAs was used as
control (Ctrl). Following treatment, HT29 cells were placed in a laminar flow chamber under a shear stress of 1 dyne/cm
2 as in A.I nA and D,
the cells attached to the endothelium were counted after 25 min in more than 5 fields per condition. *p < 0.01 (Student t test using the IL-1b
condition as reference). In B, C, E and F, representative fields are shown.
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stream of DR3 may be independent of the TRAF2 path-
way and would depend on the activation of the PI3K/
Akt pathway, presumably downstream of a Src-depen-
dent tyrosine phosphorylation of DR3 within the ITAM
motif [50,51]. This possibility is in line with the finding
that cell survival downstream of CD95/Fas is associated
with its tyrosine phosphorylation, upstream of the acti-
vation of the PI3K/AKT pathway [26]. Consistent with a
role of PI3K/NFB pathways in protecting HT29 cells
from apoptosis in response to E-selectin, we further
found that the inhibition of PI3K by LY294002 increased
the cleavage of caspase 8 in response to E-selectin (Fig-
u r e5 A ) .W ep r e v i o u s l yr e p o r t e dt h a tE R Kc o n t r i b u t e s
to protect colon cancer cells from apoptosis following
activation of DR3 by E-selectin [23]. Accordingly, the
co-inhibition of both ERK and PI3K, respectively by
PD098059 and LY294002, was associated with a
Figure 2 E-selectin does not induce apoptosis in HT29 cells. A to D, HT29 cells were left untreated (A) or were treated with E-selectin at 10
μg/ml for 4 hours (B) or 24 hours (C), or were treated with phenethyl isothiocyanate at 50 μM for 24 hours (D). Cells were fixed and stained
with Hoechst dye and examined for nuclear fragmentation. In E, 24 hours after being plated, HT29 cells were left to grow for 96 hours with or
without E-selectin or the apoptosis inducer curcumin (75 μM). At the end of the treatments, the cell survival was evaluated by their ability to
convert tetrazolium salt into formozan (WST-1 assay), which was monitored at 450 nm.
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response to E-selectin (Figure 5B). This result indicates
that both ERK and the PI3K/Akt//NFB axis contribute
to confer apoptosis resistance to colon cancer cells in
Figure 3 E-selectin mediates Src kinase-dependent
phosphorylation of Akt through DR3. A) HT29 cells were left
untreated or treated for different periods of time (5, 10,15 and 20
min) with rhE-selectin/Fc (5 μg/ml). The proteins were extracted and
separated by SDS-PAGE and transferred onto a nitrocellulose
membrane. Akt activation was analysed by western blotting with
specific anti-phospho (Ser 473)-Akt antibody. The blots was then
stripped and reprobed with antibody recognizing total Akt as
loading control. B) HT29 cells were pre-incubated or not for 30
minutes with anti-DR3 (hDR3) or anti-DR3 (DR3ecd) before being
incubated with rhE-selectin/Fc (5 μg/ml for 15 min). The proteins
were extracted and processed as in A. C) HT29 cells were pre-
treated for 2 hours with DMSO (0.1%) or LY249002 (20 μM) before
being incubated with rhE-selectin/Fc (5 μg/ml for 15 min). The
proteins were extracted and processed as in A. D) HT29 cells were
pretreated for 2 hours with DMSO (0.08%) or PP2 (10 μM) to inhibit
Src family kinases. Thereafter, the cells were left untreated or treated
with E-selectin (5 μ/ml for 15 min). The proteins were extracted and
processed as in A.
Figure 4 DR3 activation triggers NFB activation through PI3K.
HT29 cells were pre-treated for 2 hours with PI3K inhibitor
LY294002 (20 μM) or DMSO as vehicle (0.1%) and treated or not
with rhE-selectin/Fc (5 ng/ml for 15 min). Nuclear proteins were
extracted and processed for western blotting using specific
antibodies for total p65 NFB or for TATA binding protein (TBP)
used as nuclear protein control.
Figure 5 PI3K and ERK activation impairs caspase activation. A)
HT29 cells were pre-treated for 30 minutes with DMSO (0.1%) or LY
249002 (20 μM) before being incubated with rhE-selectin/Fc (5 μg/
ml for 24 hours). The proteins were extracted and were separated
by SDS-PAGE and transferred onto a nitrocellulose membrane.
Caspase-8 cleavage/activation was analysed by western blotting
using specific anti-caspase-8 antibody. B) HT29 cells were pre-
treated with MEK inhibitor PD059098 (50 μM for 60 min) with or
without PI3K inhibitor LY294002 (20 μM for 30 min) or DMSO as
vehicle (0.1% for 60 min) and treated or not with rhE-selectin/Fc (5
ng/ml for 24 hours). The proteins were extracted and were
separated by SDS-PAGE and transferred onto a nitrocellulose
membrane. Caspase-3 activation was analysed by western blotting
using a specific anti-active-caspase-3 antibody and a specific
antibody against vinculin as loading control.
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Page 8 of 12response to E-selectin. In addition, it confirms the pro-
survival function of the ERK pathway downstream of
DR3, as we previously reported [23].
Metastatic colon cancer cells express transmembrane and
cytoplasmic deletants of DR3
Next, we verified whether am u t a t i o ni nD R 3c o u l d
further contribute to the lack of apoptosis induced by E-
selectin. By using PCR approach, we cloned and
sequenced DR3 cDNA, and we found major variations
in the expression profile of DR3. From 36 different
clones, we discovered that, in addition to the full-length
version of DR3, HT29 cells expressed splice variants of
DR3. One of them is characterized by a loss of exon 6
(DR3Δ6) (Additional file 5). The joint between the last
two nucleotides of exon 5 and the first two nucleotides
of exon 7 leads to a shift in the reading frame introdu-
cing a premature stop codon, located at the beginning
of exon 8 (Figure 6A). This variant codes for a new pro-
tein whose last 37 amino acids are not found in any of
the known variants of DR3. This protein has no trans-
membrane and death domain (Figure 6B) and thus is
Figure 6 Colon carcinoma cells HT29 express a splice variant of DR3 missing the exon 6. A) Schematic representation of the normal
splicing and the splicing associated with the loss of exon 6 within DR3v2. B) Predicted amino acids sequence of DR3v2 deleted of exon 6. The
transmembrane domain is shown in the black box and the black line represents the death domain. Identical amino acid sequences are in black
and non-identical are in red. GeneBank sequence NP_003781.1 was used as reference for DR3v2. C) Total RNA from different cell lines were
extracted and were amplified by reverse transcriptase. Primers were designed to amplify by PCR the region from exon 5 to exon 7 of DR3v2.
The resulting products were run through agarose gel. D) Total RNA from SW480 or SW620 cell lines were extracted and were amplified by
reverse transcriptase. PCR reactions were carried out using specific primers amplifying region around exon 6 which produce a 97bp band for the
DR3v2Δ6. Automated sizing and relative quantification of the amplicon versus total amplicons was performed using the manufacturer’s software.
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Page 9 of 12unable to trigger apoptosis. Interestingly, by PCR ampli-
fication of the region around exon 6, we found that the
relative proportion of DR3Δ6 was higher in metastatic
colon cancer cells (HT29, HT29LMM, SW620) in com-
parison to normal colon epithelial cells (HIEC) and
endothelial cells (HUVEC, HMEC), as well as in meta-
static cancer cells that are not of colon origin (Jurkat,
Hela, MCF7, MDAMB231) (Figure 6C). Notably, it is
particularly clear that the relative level of of DR3Δ6t o
full length DR3 is higher in metastatic SW620 cells rela-
tive to non-metastatic SW480 cells taken from the pri-
mary tumor site of the same patient. In fact, more
precise quantification by targeted PCR reactions and
analysed of the amplified products by chip-based micro-
capillary electrophoresis indicated that the ratio of
DR3Δ6 to full length DR3 doubled in SW620 cells rela-
tive to SW480 (Figure 6D). These findings strongly sug-
gest that the expression of DR3Δ6 is associated with a
metastatic phenotype in colon cancer. In turn, this raises
the possibility that, during the acquisition and progres-
sion of malignancy, colon cancer cells evolved to
develop alternative splicing mechanisms favoring the
shifting of a death-receptor toward a survival receptor.
Along these lines, it was shown that a variant of DR3,
(DR3b), differs from the described DR3 isoform 2 by the
inclusion of a 28 amino-acid stretch in the extracellular
domain. Whereas DR3 was expressed in all the cell lines
and lymphoma samples tested, DR3b expression was
restricted to lymphoid T-cell and immature B-cell lines
and to some cases of follicular lymphoma. This is con-
sistent with our finding that different isoforms of DR3
can contribute to cancer [28]. It is difficult at present to
fully understand the mechanism of alternative splicing
regulation acting on DR3. One possibility relies on the
phosphorylation of serine-arginine rich proteins (SRPs)
known to be major regulators of alternative splicing in
colon cancer cells [52]. This is further supported by the
fact that PI3K which is activated by E-selectin-mediated
stimulation of DR3 also regulates the phosphorylation of
SRPs [53]. Interestingly, death decoy receptor-3 (DcR3),
another member of the TNF receptor superfamily, is a
soluble receptor that is highly expressed in various
tumors including colon cancer and that act as a negative
regulator of DR3[54]. Although, DR3Δ6 differs in
sequence from DcR3, it is possible that it also acts as a
decoy receptor for the activation of DR3 by E-selectin.
Conclusion
Overall, our study reveals that activation of DR3 by E-
selectin in HT29 cells leads to the activation of the
PI3K/NFB survival pathway. This results in cells that
are both resistant to apoptosis and which have acquired
an increased capacity to survive. We also found that
HT29 cells have developed alternative splicing
mechanisms that favor the shift of DR3 from a full
length signaling receptor to deletants devoid of death
domain and thus unable to trigger apoptosis. This is the
first time that such a bi-functional insidious mechanism
is reported to confer metastatic properties to colon can-
cer cells.
Additional material
Additional file 1: An irrelevant antibody to DR3 does not influence
the adhesion of colon cancer cells to E-selectin-expressing
endothelial cells in a laminar flow chamber. HUVECs were trypsinized
and grown for 24 hrs on gelatin-coated slides. These endothelial cells
were treated with 20 ng/ml IL-1b for 4 h to induce the expression of E-
selectin. The endothelial cell cultures were then placed in a laminar flow
chamber under a shear stress of 1 dyne/cm
2. Live HT29 cells (2 × 10
6 per
assay) stained with Calcein AM were treated with a control irrelevant
antibody (Ctrl: MOPC21) for 30 min prior to being introduced in the
medium circulating over endothelial cells. Videos were taken directly
using a camera mounted on a TE2000 fluorescence microscope at ×20
magnification to follow the adhesion of HT-29 cells to HUVECs.
Additional file 2: An anti-DR3 blocking antibody impairs the
adhesion of colon cancer cells to E-selectin-expressing endothelial
cells in a laminar flow chamber. HUVECs were trypsinized and grown
for 24 hrs on gelatin-coated slides. These endothelial cells were treated
with 20 ng/ml IL-1b for 4 h to induce the expression of E-selectin. The
endothelial cell cultures were then placed in a laminar flow chamber
under a shear stress of 1 dyne/cm
2. Live HT29 cells (2 × 10
6 per assay)
stained with Calcein AM were treated with an anti-DR3 blocking
antibody (B65) for 30 min prior to being introduced in the medium
circulating over endothelial cells. Videos were taken directly using a
camera mounted on a TE2000 fluorescence microscope at ×20
magnification to follow the adhesion of HT-29 cells to HUVECs.
Additional file 3: An irrelevant control siRNA does not influence the
adhesion of colon cancer cells to E-selectin-expressing endothelial
cells in a laminar flow chamber. HUVECs were trypsinized and grown
for 24 hrs on gelatin-coated slides. These endothelial cells were treated
with 20 ng/ml IL-1b for 4 h to induce the expression of E-selectin. The
endothelial cell cultures were then placed in a laminar flow chamber
under a shear stress of 1 dyne/cm
2. Live HT29 cells were transfected by
electroporation with control siRNA purchased from Qiagen. Tumor cells
in suspension (2 × 10
6 per assay) were labeled for 30 min with Calcein
AM and washed twice with M199 medium before being added in the
medium circulating over endothelial cells. Videos were taken directly
using a camera mounted on a TE2000 fluorescence microscope at ×20
magnification to follow the adhesion of HT-29 cells to HUVECs.
Additional file 4: Knocking down the expression of DR3 with a
human DR3 siRNA impairs the adhesion of colon cancer cells to E-
selectin-expressing endothelial cells in a laminar flow chamber.
HUVECs were trypsinized and grown for 24 hrs on gelatin-coated slides.
These endothelial cells were treated with 20 ng/ml IL-1b for 4 h to
induce the expression of E-selectin. The endothelial cell cultures were
then placed in a laminar flow chamber under a shear stress of 1 dyne/
cm
2. Live HT29 cells were transfected by electroporation with human
DR3 siRNA purchased from Qiagen. Tumor cells in suspension (2 × 10
6
per assay) were labeled for 30 min with Calcein AM and washed twice
with M199 medium before being added in the medium circulating over
endothelial cells. Videos were taken directly using a camera mounted on
a TE2000 fluorescence microscope at ×20 magnification to follow the
adhesion of HT-29 cells to HUVECs.
Additional file 5: Sequence alignment between Dr3v2 and splice
variant of DR3 missing the exon 6. Total RNA from HT29 cells were
extracted and were amplified by reverse transcriptase. The resulting
cDNAs were amplified by PCR using primers that bind to all DR3
isoforms outside of the reading frame. A second round of PCR was done
using a 3’ primer outside the reading frame and a 5’ primer just inside
the reading frame. These final cDNAs were cloned and then sequenced.
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reference sequence NM_003790.2. Grey colored box sequences and
blank sequences represent alternating exons.
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